<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Royalty Pharma Plc — News on 6ix</title>
    <link>https://6ix.com/company/royalty-pharma-plc</link>
    <description>Latest news and press releases for Royalty Pharma Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 17:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/royalty-pharma-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b9fe78dffbe2df115b2d.webp</url>
      <title>Royalty Pharma Plc</title>
      <link>https://6ix.com/company/royalty-pharma-plc</link>
    </image>
    <item>
      <title>Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-launches-global-translational-prize-to-recognize-breakthrough-scientific-innovation</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-launches-global-translational-prize-to-recognize-breakthrough-scientific-innovation</guid>
      <pubDate>Tue, 21 Apr 2026 17:00:00 GMT</pubDate>
      <description>NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It will include a $1 million award distributed among one or more established scientists whose work has trans</description>
    </item>
    <item>
      <title>Royalty Pharma Declares Second Quarter 2026 Dividend</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-declares-second-quarter-2026-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-declares-second-quarter-2026-dividend</guid>
      <pubDate>Fri, 17 Apr 2026 12:30:00 GMT</pubDate>
      <description>NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical indust</description>
    </item>
    <item>
      <title>Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-to-announce-first-quarter-2026-financial-results-on-may-6-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-to-announce-first-quarter-2026-financial-results-on-may-6-2026</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on</description>
    </item>
    <item>
      <title>Royalty Pharma Announces R&amp;D Funding Collaboration for Chronic Immune-Mediated Diseases</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announces-randd-funding-collaboration-for-chronic-immune-mediated-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announces-randd-funding-collaboration-for-chronic-immune-mediated-diseases</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&amp;D) co-funding agreement with</description>
    </item>
    <item>
      <title>Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update-1</guid>
      <pubDate>Fri, 27 Mar 2026 13:00:00 GMT</pubDate>
      <description>Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys’ Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysB</description>
    </item>
    <item>
      <title>Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-appoints-lucas-glass-as-head-of-artificial-intelligence</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-appoints-lucas-glass-as-head-of-artificial-intelligence</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial</description>
    </item>
    <item>
      <title>Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma&apos;s Global Platform</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-appoints-kenneth-sun-as-senior-vice-president-and-head-of-asia-to-expand-royalty-pharmas-global-platform</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-appoints-kenneth-sun-as-senior-vice-president-and-head-of-asia-to-expand-royalty-pharmas-global-platform</guid>
      <pubDate>Tue, 03 Mar 2026 02:15:00 GMT</pubDate>
      <description>Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company&apos;s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.</description>
    </item>
    <item>
      <title>Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-and-zymeworks-enter-into-dollar250-million-royalty-backed-note-financing-1</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-and-zymeworks-enter-into-dollar250-million-royalty-backed-note-financing-1</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on</description>
    </item>
    <item>
      <title>Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/zymeworks-and-royalty-pharma-enter-into-dollar250-million-royalty-backed-note-financing-1</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/zymeworks-and-royalty-pharma-enter-into-dollar250-million-royalty-backed-note-financing-1</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on</description>
    </item>
    <item>
      <title>Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-to-present-at-td-cowens-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-to-present-at-td-cowens-46th-annual-health-care-conference</guid>
      <pubDate>Thu, 26 Feb 2026 21:15:00 GMT</pubDate>
      <description>NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical r</description>
    </item>
    <item>
      <title>Royalty Pharma Reports Q4 and Full Year 2025 Results</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-reports-q4-full-120000125</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-reports-q4-full-120000125</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
      <description>Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced f</description>
    </item>
    <item>
      <title>Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announce-fourth-quarter-211500431</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announce-fourth-quarter-211500431</guid>
      <pubDate>Tue, 20 Jan 2026 21:15:00 GMT</pubDate>
      <description>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conferenc</description>
    </item>
    <item>
      <title>Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-highlight-accomplishments-business-121500636</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-highlight-accomplishments-business-121500636</guid>
      <pubDate>Mon, 12 Jan 2026 12:15:00 GMT</pubDate>
      <description>Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, includ</description>
    </item>
    <item>
      <title>Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-teva-enter-agreement-221500379</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-teva-enter-agreement-221500379</guid>
      <pubDate>Sun, 11 Jan 2026 22:15:00 GMT</pubDate>
      <description>Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalt</description>
    </item>
    <item>
      <title>Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/teva-and-royalty-pharma-enter-agreement-accelerate-development-potential-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/teva-and-royalty-pharma-enter-agreement-accelerate-development-potential-treatment</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support</description>
    </item>
    <item>
      <title>Royalty Pharma Announces Dividend Increase</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announces-dividend-increase-133000237</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-announces-dividend-increase-133000237</guid>
      <pubDate>Fri, 09 Jan 2026 13:30:00 GMT</pubDate>
      <description>NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest</description>
    </item>
    <item>
      <title>Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-acquires-remaining-royalty-interest-roches-evrysdi-240-million-and</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-acquires-remaining-royalty-interest-roches-evrysdi-240-million-and</guid>
      <pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
      <description>Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE)</description>
    </item>
    <item>
      <title>Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-acquires-royalty-interest-nuvalents-neladalkib-and-zidesamtinib-315</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-acquires-royalty-interest-nuvalents-neladalkib-and-zidesamtinib-315</guid>
      <pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
      <description>NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in</description>
    </item>
    <item>
      <title>Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-and-denali-therapeutics-announce-275-million-royalty-funding-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/royalty-pharma-and-denali-therapeutics-announce-275-million-royalty-funding-agreement</guid>
      <pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
      <description>NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI)</description>
    </item>
    <item>
      <title>Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement</title>
      <link>https://6ix.com/company/royalty-pharma-plc/news/denali-therapeutics-and-royalty-pharma-announce-275-million-royalty-funding-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/royalty-pharma-plc/news/denali-therapeutics-and-royalty-pharma-announce-275-million-royalty-funding-agreement</guid>
      <pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX)</description>
    </item>
  </channel>
</rss>